Differential effects of fluticasone on extracellular matrix production by airway and parenchymal fibroblasts in severe COPD

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 305, Issue 8, 2013, Pages

  Brandsma, Corry Anke ^a,b   Timens, Wim ^a,b   Jonker, Marnix R ^a,b   Rutgers, Bea ^a   Noordhoek, Jacobien A ^a,b   Postma, Dirkje S ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GRIAC Research Center   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Tissue repair and remodeling

Indexed keywords

BIGLYCAN; CIGARETTE SMOKE; DECORIN; FLUTICASONE; PROCOLLAGEN; SMAD PROTEIN; STEROID; TRANSFORMING GROWTH FACTOR BETA;

AIRWAY; AIRWAY OBSTRUCTION; ARTICLE; CELL HETEROGENEITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFECT; EMPHYSEMA; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER PARENCHYMA; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN SECRETION; SMOKING; TISSUE REPAIR;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; TISSUE REPAIR AND REMODELING;

ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BIGLYCAN; CELLS, CULTURED; DECORIN; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; LUNG; PROCOLLAGEN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING; TRANSFORMING GROWTH FACTOR BETA;

EID: 84885576774     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00152.2013     Document Type: Article

References (24)

1. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320: 1297-1303, 2000.
2. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: 449-456, 2003.
3. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178: 332-338, 2008.
4. de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS, van Krieken JH. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158: 1951-1957, 1998.
5. Eickelberg O, Kohler E, Reichenberger F, Bertschin S, Woodtli T, Erne P, Perruchoud AP, Roth M. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-fj1 and TGF-fj3. Am J Physiol Lung Cell Mol Physiol 276: L814-L824, 1999.
6. GOLD Committee. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Online].
7. Goulet S, Bihl MP, Gambazzi F, Tamm M, Roth M. Opposite effect of corticosteroids and long-acting beta(2)-agonists on serum- and TGF-beta(1)-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol 210: 167-176, 2007.
8. Hallgren O, Nihlberg K, Dahlback M, Bjermer L, Eriksson LT, Erjefalt JS, Lofdahl CG, Westergren-Thorsson G. Altered fibroblast proteoglycan production in COPD. Respir Res 11: 1465-9921, 2010.
9. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4: 435-459, 2009.
10. Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS. Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol 70: 518-531, 2006.
11. Konigshoff M, Kneidinger N, Eickelberg O. TGF-beta signaling in COPD: deciphering genetic and cellular susceptibilities for future therapeutic regimen. Swiss Med Wkly 139: 554-563, 2009.
12. Kotaru C, Schoonover KJ, Trudeau JB, Huynh ML, Zhou X, Hu H, Wenzel SE. Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med 173: 11: 1208-1215, 2006.
13. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 151: 517-527, 2009.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
15. Noordhoek JA, Postma DS, Chong LL, Menkema L, Kauffman HF, Timens W, van Straaten JF, van der Geld YM. Different modulation of decorin production by lung fibroblasts from patients with mild and severe emphysema. COPD 2: 17-25, 2005.
16. Noordhoek JA, Postma DS, Chong LL, Vos JT, Kauffman HF, Timens W, van Straaten JF. Different proliferative capacity of lung fibroblasts obtained from control subjects and patients with emphysema. Exp Lung Res 29: 291-302, 2003.
17. Pechkovsky DV, Hackett TL, An SS, Shaheen F, Murray LA, Knight DA. Human lung parenchyma but not proximal bronchi produces fibroblasts with enhanced TGF-beta signaling and alpha-SMA expression. Am J Respir Cell Mol Biol 43: 641-651, 2010.
18. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabe-dian S, Peterson S, Olsson H. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21: 74-81, 2003.
19. Todorova L, Bjermer L, Westergren-Thorsson G, Miller-Larsson A. TGFbeta-induced matrix production by bronchial fibroblasts in asthma: budesonide and formoterol effects. Respir Med 105: 1296-1307, 2011.
20. van Straaten JF, Coers W, Noordhoek JA, Huitema S, Flipsen JT, Kauffman HF, Timens W, Postma DS. Proteoglycan changes in the extracellular matrix of lung tissue from patients with pulmonary emphysema. Mod Pathol 12: 697-705, 1999.
21. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Co-chrane Database Syst Rev 2: CD002991, 2007.
22. Zandvoort A, Postma DS, Jonker MR, Noordhoek JA, Vos JT, Timens W. Smad gene expression in pulmonary fibroblasts: indications for defective ECM repair in COPD. Respir Res 9: 1465-1993, 2008.
23. Zandvoort A, Postma DS, Jonker MR, Noordhoek JA, Vos JT, van der Geld YM, Timens W. Altered expression of the Smad signalling pathway: implications for COPD pathogenesis. Eur Respir J 28: 533-541, 2006.
24. Zhou X, Wu W, Hu H, Milosevic J, Konishi K, Kaminski N, Wenzel SE. Genomic differences distinguish the myofibroblast phenotype of distal lung fibroblasts from airway fibroblasts. Am J Respir Cell Mol Biol 45: 1256-1262, 2011.